Beta Drugs Fair Value
Beta Drugs (BETA) average fair value is ₹433.74 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹1400.7 (-69.03%), fair value range ₹166.46–₹946.76. For live price and a broader fundamental view, visit Beta Drugs stock price NSE .
Fair Value Analysis Export
BETA Fair Value vs Current Price — Valuation Summary
BETA average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore BETA investment value to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
BETA Fair Value Analysis — Data Sources & Coverage
Beta Drugs financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine BETA earnings report for recent quarterly revenue, profit and EPS trends.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
BETA vs Healthcare Sector Peers — P/E, P/B & Market Cap
Beta Drugs P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Sanofi Consumer Healthca… | SANOFICONR | 43.83 | 27.4 | ₹10,638 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Sat Kartar Shopping | SATKARTAR | 29.05 | 5.53 | ₹307 |
| Jeena Sikho Lifecare | JSLL | 40.04 | 22.87 | ₹8,290 |
| Accretion Pharmaceuticals | ACCPL | 10.92 | 1.65 | ₹78 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.